Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback